[go: up one dir, main page]

CN114939107A - Hydrogen slow-release solution and preparation method and application thereof - Google Patents

Hydrogen slow-release solution and preparation method and application thereof Download PDF

Info

Publication number
CN114939107A
CN114939107A CN202210533301.5A CN202210533301A CN114939107A CN 114939107 A CN114939107 A CN 114939107A CN 202210533301 A CN202210533301 A CN 202210533301A CN 114939107 A CN114939107 A CN 114939107A
Authority
CN
China
Prior art keywords
magnesium
polylactic acid
hydrogen
solution
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210533301.5A
Other languages
Chinese (zh)
Inventor
袁涛
包倪荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eastern Theater General Hospital of PLA
Original Assignee
Eastern Theater General Hospital of PLA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Theater General Hospital of PLA filed Critical Eastern Theater General Hospital of PLA
Priority to CN202210533301.5A priority Critical patent/CN114939107A/en
Publication of CN114939107A publication Critical patent/CN114939107A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicine preparation. The invention provides a hydrogen slow-release solution and a preparation method and application thereof. The hydrogen sustained-release solution is prepared by taking levorotatory polylactic acid, a magnesium simple substance, chloroform and a phosphate buffer solution as raw materials. Mixing levorotatory polylactic acid, a magnesium simple substance and chloroform, and then carrying out electrostatic spinning to obtain magnesium-based microspheres; and mixing the magnesium-based microspheres and the phosphate buffer solution and stirring to obtain the hydrogen slow-release solution. The magnesium simple substance is successfully wrapped in the L-polylactic acid by the electrostatic spinning technology, so that magnesium atoms can be effectively prevented from directly contacting with air or solution, magnesium particles are gradually released along with the decomposition of the L-polylactic acid in a liquid environment, and then the hydrogen which reacts to generate a therapeutic effect is effectively and slowly released. The preparation method provided by the invention has mature process, can effectively obtain a finished product, and is convenient for large-scale preparation.

Description

Hydrogen slow-release solution and preparation method and application thereof
Technical Field
The invention relates to the technical field of medicine preparation, in particular to a hydrogen sustained-release solution and a preparation method and application thereof.
Background
Rotator cuff repair is a complex procedure. It is generally believed that the lack of endogenous stem cells, poor blood supply and local inflammatory microenvironment are responsible for the failure of fibrocartilage interface regeneration following rotator cuff injury repair. Mesenchymal Stem Cells (MSCs) play a key role in fibrocartilage regeneration, and MSCs mobilize to the injury site after injury, proliferate and aggregate around the injury site, however, there is no suitable method for providing a microenvironment for aggregation and differentiation of MSCs in tendon repair. Magnesium ions can regulate cell behaviors such as cell adhesion, migration, proliferation and the like, can also regulate inflammation/immune response, stimulate fibrocartilage formation and promote tendon to bone healing. The current research shows that the magnesium alloy has great potential in the aspect of orthopedic implants due to good biocompatibility and mechanical properties. Research reports indicate that magnesium can increase fibrocartilage matrix synthesis of MSCs, enhance homing of endogenous MSCs at a diseased site, promote formation of fibrocartilage interface at a repaired site, and provide Mg at a damaged site 2+ May be a safe and effective method for promoting the regeneration of fibrocartilage.
Meanwhile, inflammation and oxidative stress are closely related to the pathology of many human diseases, and play a key role in the occurrence and development of many joint diseases, resulting in morphological and histological changes in the tissues within the joints. Studies have shown that inflammation in osteoarthritis is significantly associated with activated macrophages that overproduce Reactive Oxygen Species (ROS), leading to chondrocyte apoptosis, and also induce the expression of proinflammatory cytokines including interleukins IL-1, IL-6, and tumor necrosis factor TNF- α. Cartilage, tendons, synovium, etc. are the major components of joints, and inflammatory responses of these tissue cells and apoptosis due to oxidative stress are the major problems in the progression of joint disease. Hydrogen (H) 2 ) It is considered to be a medical gas having an anti-inflammatory action which selectively reduces highly cytotoxic oxidative radicals such as hydroxyl radicals and peroxynitrite in diseased cells, but does not affect the metabolic redox reaction of normal cells, nor interfere with the participation in cell signal transduction. H 2 Is nontoxic even at high concentrations and has been demonstrated directly in animal modelsInhalation H 2 The gas, oral hydrogen-rich water or intravenous hydrogen-containing physiological saline can be used for treating inflammation related diseases. However, in these methods, H 2 Bioavailability is often poor locally in body fluids and inflammation because of its low solubility in aqueous solutions (about 0.8mM), which limitation can be overcome by using a local sustained release system that is capable of continuously providing high therapeutic concentrations of gaseous H in diseased tissue 2 . Therefore, there is an urgent need to develop a novel biomaterial that provides conditions for the differentiation of endogenous stem cells to regenerate fibrocartilage at the tendon-bone interface, and at the same time, can control inflammation and reduce oxidative stress, and improve local microenvironment.
Disclosure of Invention
The invention aims to overcome the defects in the prior art and provides a hydrogen slow-release solution and a preparation method and application thereof.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a hydrogen slow-release solution, which comprises the following preparation raw materials in proportion: levorotatory polylactic acid, magnesium simple substance, chloroform and phosphate buffer solution;
the mass ratio of the levorotatory polylactic acid to the magnesium simple substance is 150-170: 0.8 to 8;
the mass-volume ratio of the levorotatory polylactic acid to the chloroform is 150-170 mg: 0.5-1.5 mL;
the mass-volume ratio of the levorotatory polylactic acid to the phosphate buffer solution is 150-170 mg: 0.5-1.5 mL.
Preferably, the particle size of the magnesium simple substance is 140-180 pm, and the concentration of the phosphate buffer solution is 0.1-0.3 mol/L.
The invention also provides a preparation method of the hydrogen sustained-release solution, which comprises the following steps:
(1) mixing levorotatory polylactic acid, a magnesium simple substance and chloroform, and then carrying out electrostatic spinning to obtain magnesium-based microspheres;
(2) and mixing the magnesium-based microspheres and the phosphate buffer solution and stirring to obtain the hydrogen slow-release solution.
Preferably, the mixing mode in the step (1) is stirring, the rotating speed of the stirring is 500-700 rpm, and the time is 0.5-1.5 h.
Preferably, the injection speed of the electrostatic spinning in the step (1) is 0.6-1 mL/h.
Preferably, the humidity of the electrostatic spinning in the step (1) is 46-50%.
Preferably, the voltage of the electrostatic spinning in the step (1) is 6-6.4 kV.
Preferably, the rotation speed of the stirring in the step (2) is 500-700 rpm.
Preferably, the stirring time in the step (2) is 0.5-1.5 h.
The invention also provides application of the hydrogen sustained-release solution in preparing a medicine for treating rotator cuff repair.
The invention provides a hydrogen slow-release solution and a preparation method and application thereof. The hydrogen sustained-release solution is prepared by taking levorotatory polylactic acid, a magnesium simple substance, chloroform and a phosphate buffer solution as raw materials. Mixing levorotatory polylactic acid, a magnesium simple substance and chloroform, and then carrying out electrostatic spinning to obtain magnesium-based microspheres; and mixing the magnesium-based microspheres and the phosphate buffer solution and stirring to obtain the hydrogen slow-release solution. The magnesium simple substance is successfully wrapped in the L-polylactic acid by the electrostatic spinning technology, so that magnesium atoms can be effectively prevented from directly contacting with air or solution, magnesium particles are gradually released along with the decomposition of the L-polylactic acid in a liquid environment, and then the hydrogen which reacts to generate a therapeutic effect is effectively and slowly released. The preparation method provided by the invention has mature process, can effectively obtain a finished product, and is convenient for large-scale preparation.
Drawings
FIG. 1 is an electron microscope image of particles without magnesium and particles with 0.8mg of magnesium added in example 1;
FIG. 2 is a schematic diagram showing the action of the hydrogen sustained-release solution in example 1;
FIG. 3 is a graph showing changes in pH of the hydrogen sustained-release solution in example 1;
FIG. 4 is an elemental analysis chart of the hydrogen sustained-release solution in example 1;
FIG. 5 is a hydrogen evolution diagram of a hydrogen evolution solution with an elemental magnesium addition of 0.8mg according to example 1.
Detailed Description
The invention provides a hydrogen slow-release solution, which comprises the following preparation raw materials in proportion: levorotatory polylactic acid, magnesium simple substance, chloroform and phosphate buffer solution;
the mass ratio of the levorotatory polylactic acid to the magnesium simple substance is 150-170: 0.8 to 8;
the mass-volume ratio of the levorotatory polylactic acid to the chloroform is 150-170 mg: 0.5-1.5 mL;
the mass-volume ratio of the levorotatory polylactic acid to the phosphate buffer solution is 150-170 mg: 0.5-1.5 mL.
In the invention, the mass ratio of the levorotatory polylactic acid to the magnesium simple substance is preferably 155-165: 1 to 7, and more preferably 156 to 164: 2 to 6, more preferably 158 to 162: 3 to 5.
In the invention, the mass-to-volume ratio of the L-polylactic acid to the chloroform is preferably 155-165 mg: 0.6-1.4 mL, more preferably 156-164 mg: 0.8-1.2 mL, more preferably 158-162 mg: 0.9-1.1 mL.
In the invention, the mass-volume ratio of the L-polylactic acid to the phosphate buffer solution is preferably 155-165 mg: 0.6-1.4 mL, more preferably 156-164 mg: 0.8-1.2 mL, more preferably 158-162 mg: 0.9-1.1 mL.
In the invention, the particle size of the magnesium elementary substance is preferably 140-180 pm, more preferably 150-170 pm, and more preferably 155-165 pm; the concentration of the phosphate buffer solution is preferably 0.1-0.3 mol/L, more preferably 0.15-0.25 mol/L, and even more preferably 0.2 mol/L.
The invention also provides a preparation method of the hydrogen slow-release solution, which comprises the following steps:
(1) mixing levorotatory polylactic acid, a magnesium simple substance and chloroform, and then carrying out electrostatic spinning to obtain magnesium-based microspheres;
(2) and mixing the magnesium-based microspheres and the phosphate buffer solution and stirring to obtain the hydrogen slow-release solution.
In the invention, the mixing mode in the step (1) is preferably stirring, and the rotation speed of the stirring is preferably 500-700 rpm, more preferably 550-650 rpm, and more preferably 580-620 rpm; the time is preferably 0.5 to 1.5 hours, more preferably 0.6 to 1.4 hours, and still more preferably 0.8 to 1.2 hours.
In the invention, the injection speed of the electrostatic spinning in the step (1) is preferably 0.6-1 mL/h, more preferably 0.7-0.9 mL/h, and even more preferably 0.75-0.85 mL/h.
In the present invention, the humidity of the electrostatic spinning in the step (1) is preferably 46 to 50%, more preferably 47 to 49%, and still more preferably 47.5 to 48.5%.
In the invention, the voltage of the electrostatic spinning in the step (1) is preferably 6-6.4 kV, more preferably 6.1-6.3 kV, and even more preferably 6.15-6.25 kV.
In the invention, the anode of the electrostatic spinning is provided with an injector needle, the cathode of the electrostatic spinning is provided with an aluminum foil receiving plate, and microspheres on the aluminum foil receiving plate are collected for later use.
In the present invention, the rotation speed of the stirring in the step (2) is preferably 500 to 700rpm, more preferably 550 to 650rpm, and even more preferably 580 to 620 rpm.
In the invention, the stirring time in the step (2) is preferably 0.5 to 1.5 hours, more preferably 0.6 to 1.4 hours, and even more preferably 0.8 to 1.2 hours.
The invention also provides application of the hydrogen sustained-release solution in preparing a medicine for treating rotator cuff repair.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
Mixing 0.16g of L-polylactic acid, a magnesium simple substance with the particle size of 160pm and 1mL of chloroform, stirring at 600rpm for 1h, then carrying out electrostatic spinning, using an injector needle for an anode, using an aluminum foil receiving plate for a cathode, and carrying out injection at the speed of 0.8mL/h, the humidity of 48% and the voltage of 6.2kV to obtain magnesium-based microspheres;
the single variable is the addition of the magnesium simple substance, which is respectively 0, 0.8, 1, 2, 4 and 8mg, and different magnesium-based microspheres are prepared.
Mixing the magnesium-based microspheres with 1mL of phosphate buffer solution with the concentration of 0.2mol/L, and stirring at the rotating speed of 600rpm for 1h to obtain the hydrogen slow-release solution.
The magnesium-based microspheres in this example, in which the amount of magnesium added was 0.8mg, and the microspheres without magnesium were observed under an electron microscope, and the results are shown in FIG. 1. In FIG. 1, A is the microsphere without magnesium, B is the microsphere with 0.8mg magnesium, and it can be seen from the figure that the particle in A is spherical, the particle diameter is 5.5 + -1.2 μm, the particle diameter in B is 12.1 + -2.3 μm, the magnesium microparticle is wrapped in the PLLA microparticle, and the magnesium microparticle is gradually released along with the catabolism of PLLA. The schematic diagram of the hydrogen sustained-release solution prepared in this example is shown in fig. 2, Mg particles are gradually released along with the decomposition of PLLA in a liquid environment, and then H which reacts to generate a therapeutic effect is effectively and slowly released 2 。
The results of the tests on the different hydrogen release systems prepared in this example are shown in fig. 3, where 0.16g PLLA is added to 1mL chloroform, and the local pH value is relatively safe and stable when the magnesium content is 0.8 mg.
The hydrogen slow release system prepared in this example was subjected to elemental analysis, and the results are shown in fig. 4, from which it can be seen that the slow release system contains Mg element.
The hydrogen release system with magnesium content of 0.8mg prepared in this example was used to release hydrogen, and the results are shown in FIG. 5, from which it can be seen that H was detected 2 The test results of the gas release period and the release amount show that the release amount can be maintained to be higher in 8 days, the release amount is the largest in 1 day, and meanwhile, the pH is not in a safe range, so that the slow release system can be used in 2 days of incubation in PBS liquid, and the effective release amount with relatively higher concentration can be ensured under the condition of ensuring safety.
From the above embodiments, the invention provides a hydrogen sustained-release solution, and a preparation method and an application thereof. According to the invention, the magnesium simple substance is successfully wrapped in the L-polylactic acid by the electrostatic spinning technology, so that magnesium atoms can be effectively prevented from directly contacting with air or solution, magnesium particles are gradually released along with the decomposition of the L-polylactic acid in a liquid environment, and then the magnesium particles are effectively and slowly released to react to generate hydrogen with a therapeutic effect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.

Claims (10)

1. The hydrogen slow-release solution is characterized by comprising the following preparation raw materials in proportion: levorotatory polylactic acid, magnesium simple substance, chloroform and phosphate buffer solution;
the mass ratio of the levorotatory polylactic acid to the magnesium simple substance is 150-170: 0.8 to 8;
the mass-volume ratio of the levorotatory polylactic acid to the chloroform is 150-170 mg: 0.5-1.5 mL;
the mass-volume ratio of the levorotatory polylactic acid to the phosphate buffer solution is 150-170 mg: 0.5-1.5 mL.
2. The hydrogen slow-release solution as claimed in claim 1, wherein the particle size of the magnesium is 140-180 pm, and the concentration of the phosphate buffer is 0.1-0.3 mol/L.
3. The method for producing a hydrogen gas sustained-release solution according to claim 1 or 2, comprising the steps of:
(1) mixing levorotatory polylactic acid, a magnesium simple substance and chloroform, and then carrying out electrostatic spinning to obtain magnesium-based microspheres;
(2) and mixing the magnesium-based microspheres and the phosphate buffer solution and stirring to obtain the hydrogen slow-release solution.
4. The method according to claim 3, wherein the mixing in step (1) is performed by stirring at a rotation speed of 500-700 rpm for 0.5-1.5 h.
5. The preparation method according to claim 3 or 4, wherein the electrospinning in step (1) has a bolus rate of 0.6 to 1 mL/h.
6. The method according to claim 5, wherein the electrospinning in the step (1) has a humidity of 46 to 50%.
7. The method according to claim 3 or 5, wherein the voltage of the electrospinning in the step (1) is 6 to 6.4 kV.
8. The method according to claim 7, wherein the stirring in the step (2) is performed at a rotation speed of 500 to 700 rpm.
9. The method according to claim 3 or 8, wherein the stirring time in the step (2) is 0.5 to 1.5 hours.
10. Use of a hydrogen gas evolving solution according to claim 1 or 2 for the manufacture of a medicament for the treatment of rotator cuff repair.
CN202210533301.5A 2022-05-17 2022-05-17 Hydrogen slow-release solution and preparation method and application thereof Pending CN114939107A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210533301.5A CN114939107A (en) 2022-05-17 2022-05-17 Hydrogen slow-release solution and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210533301.5A CN114939107A (en) 2022-05-17 2022-05-17 Hydrogen slow-release solution and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN114939107A true CN114939107A (en) 2022-08-26

Family

ID=82906361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210533301.5A Pending CN114939107A (en) 2022-05-17 2022-05-17 Hydrogen slow-release solution and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114939107A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210187158A1 (en) * 2017-04-04 2021-06-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mg alloy mesh reinforced polymer/ecm hybrid scaffolds for critical-sized bone defect regeneration
CN114288481A (en) * 2022-01-25 2022-04-08 点云生物(杭州)有限公司 Multilayer composite medicine-carrying guided bone regeneration membrane and preparation method thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210187158A1 (en) * 2017-04-04 2021-06-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mg alloy mesh reinforced polymer/ecm hybrid scaffolds for critical-sized bone defect regeneration
CN114288481A (en) * 2022-01-25 2022-04-08 点云生物(杭州)有限公司 Multilayer composite medicine-carrying guided bone regeneration membrane and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAOJUN CHEN 等: "Sustained release of magnesium ions mediated by injectable self-healing adhesive hydrogel promotes fibrocartilaginous interface regeneration in the rabbit rotator cuff tear model", 《CHEMICAL ENGINEERING JOURNAL》 *
HUAN ZHOU 等: "Fabrication of novel poly(lactic acid)/amorphous magnesium phosphate bionanocomposite fibers for tissue engineering applications via electrospinning", 《MATERIALS SCIENCE AND ENGINEERING C 33》 *

Similar Documents

Publication Publication Date Title
CN101736430B (en) Method for preparing silk fibroin nano-fibre with skin-care effect
CN106729928B (en) Polyvinyl alcohol/sodium alginate/hydroxyapatite composite fiber membrane and preparation method and application thereof
CN113045528B (en) A kind of metal-catechin composite nanomaterial and its preparation method and application
CN108310470B (en) Sustained and controlled release oxygen microsphere, preparation method and application thereof
CN112494463B (en) Berberine/mineralized collagen composite membrane as well as preparation method and application thereof
Song et al. Macroporous granular hydrogels functionalized with aligned architecture and small extracellular vesicles stimulate osteoporotic tendon‐to‐bone healing
CN104611783A (en) Method for preparing nanofiber by electrostatic spinning, nanofiber obtained with method and application of nanofiber
CN106362202A (en) Hydrogel with microcurrent and medicine slow-release function and preparation method and application
CN102977381A (en) Wild antheraea pernyi silk fibroin microsphere and preparation method thereof
CN105617459A (en) Preparation method for nano polypyrrole chitin nerve conduit
CN110257955B (en) Electrostatic spinning nanofiber preparation process
CN101134784B (en) Agarose and hyaluronic acid graft and its preparation method and application
CN111588912A (en) Multifunctional fibrous membrane for bone tissue regeneration and preparation method thereof
CN112494723A (en) Piezoelectric support and preparation method and application thereof
CN110591126A (en) Injectable magnetic hydrogel and preparation method thereof
CN118416023A (en) Bionic nano delivery system M@RCPDA nanoparticle for idiopathic pulmonary fibrosis treatment and preparation method thereof
CN117797314A (en) An injectable filler capable of stimulating collagen regeneration and remodeling, and its preparation method and application
Liu et al. An easy nanopatch promotes peripheral nerve repair through wireless ultrasound‐electrical stimulation in a band‐aid‐like way
He et al. An injectable and retrievable bioartificial pancreas fabricated by time-sequentially assembling islets-laden microgels for minimally invasive treatment of type 1 diabetes
CN113831453B (en) A temperature-responsive hyaluronic acid, hydrogel, preparation method and application thereof
CN114939107A (en) Hydrogen slow-release solution and preparation method and application thereof
CN110180032A (en) A kind of coaxial electrostatic spinning nano fiber scaffold and its preparation method and application carrying medicine controlled release
CN114533763A (en) Novel method for culturing calculus bovis electric calculi in vitro
TWI750737B (en) Use of bio-transformed bear bile powder in preparation of medicines for treating lps-induced pulmonary inflammation
CN114796263A (en) Sodium hyaluronate hydrogen sustained-release solution and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination